| Name | Title | Contact Details |
|---|
At iA, we partner with our customers to transform pharmacy by deepening the patient-pharmacist relationship, enhancing patient safety and increasing operational efficiency.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.
Zhejiang Haichang is a biopharmaceutical company based in Hangzhou, China. They specialize in the development of mRNA vaccines, nucleic acid drug delivery, and lipid nanoparticle technologies.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns` programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns` investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.
PBM consulting, provider nnetwork strategies, rebate benchmarking, global drug sourcing, client pricing, market assessments, MAC management, rebate aggregation.